Metropolis, Roche Launch Groundbreaking HPV DNA Test for Cervical Cancer Screening

Metropolis Healthcare and Roche Diagnostics India have joined forces to introduce a revolutionary self-sampling HPV DNA test for cervical cancer screening in India. Launched on February 4, 2025, this FDA-approved and WHO-prequalified test detects 14 high-risk HPV types, offering a convenient and acc...

Metropolis Healthcare and Roche Diagnostics India have joined forces to introduce a revolutionary self-sampling HPV DNA test for cervical cancer screening in India. Launched on February 4, 2025, this FDA-approved and WHO-prequalified test detects 14 high-risk HPV types, offering a convenient and accessible solution for early detection. With India contributing to 21% of global cervical cancer cases, this initiative aims to increase screening rates, particularly in underserved areas. The test empowers women to take control of their health, potentially saving thousands of lives through early intervention. Source: ANI News, Business Standard